Clever Culture Systems Limited (CC5.AX)
Clever Culture Systems Limited operates in the Medical - Diagnostics & Research industry of the Healthcare sector, headquartered in Adelaide, SA, AU. The stock last traded at $0.02, up 14.29% on the session, giving a market capitalisation of $34.9M. Its beta of 1.69 implies it has historically moved more than the broad market.
Based in Adelaide, Australia, Clever Culture Systems Limited, established in 2004, focuses on the innovation, development, and market launch of advanced technological solutions for the medical industry. The company operates internationally, serving markets in Australia, the United States, Sweden, the United Kingdom, China, the Netherlands, and Germany. Its core offering is the Automated Plate Assessment System (APAS), which efficiently images, analyzes, and interprets microbiology culture plates, primarily assisting microbiology laboratories and the pharmaceutical manufacturing sector. The company's portfolio also includes Digital Microbiology and specialized APAS modules—artificial intelligence algorithms designed to enable digital reading of culture plates when integrated with the APAS Independence system. Additionally, Clever Culture Systems is advancing its APAS intelligent imaging technology for diverse applications, including urine screening, infection control testing, and assessing antimicrobial susceptibility. Formerly known as LBT Innovations Limited, the company adopted its current name in November 2024.
Clever Culture Systems Limited is most often compared with the following Healthcare names: